Angiotensin receptor blockers (ARBs) are efficacious in terms of reducing blood pressure in hypertensive patients. With a placebo-like side-effect profile, the adherence to drugs in this class is higher than with other antihypertensjye agents. Recent trials have demonstrated the benefit of ARBs in hypertensive patients with diabetes, and the benefit of ARBs in regressing left ventricular hypertrophy. Research is currently being carried out to evaluate whether ARBs are beneficial in the treatment of patients with heart failure and after myocardial infarction. This article reviews the evidence underlying the use of ARBs in clinical practice, in view of the recent British Hypertension Society (BHS) recommendations for their use in the UK.